Acumen Pharmaceuticals Financials - Benzinga

Acumen Pharmaceuticals Inc

ABOSNASDAQ

Trade with Public

Trade with Public

$2.92

-0.11-3.63%

At close: Aug 28, 5:00 PM EST

$3.10

0.186.16%

After Hours: Aug 28, 9:19 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Acumen Pharmaceuticals Financials

Acumen Pharmaceuticals (ABOS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Acumen Pharmaceuticals Reports Cash Balance Of $110.2M As Of June 30, 2026, Expected to Cash Runway Into Early 2027

Benzinga Newsdesk

PRO
Acumen Pharmaceuticals Q2 EPS $(0.45) Misses $(0.34) Estimate

Benzinga Newsdesk

Earnings Scheduled For May 12, 2026

Benzinga Insights

PRO
Acumen Pharmaceuticals Q1 EPS $(0.33) Beats $(0.36) Estimate

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 31.25 percent increase over losses of $(0.48) per share

Benzinga Newsdesk

PRO
Acumen Pharmaceuticals Q4 EPS $(0.41) Beats $(0.43) Estimate

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.43) by 5.09 percent. This is a 33.87 percent increase over losses of $(0.62) per share

Benzinga Newsdesk

Earnings Scheduled For March 26, 2026

Benzinga Insights